Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of April 2026. The filing, dated April 23, 2026, serves primarily to incorporate a press release (Exhibit 99.1) by reference into the company's active registration statements (Form F-3 and Form S-8).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to update registration statements with a press release and does not contain a financial statement or detailed operational data.
Material Changes
No material changes to financial results or operations are detailed within the text of this Form 6-K. The filing references the company's Annual Report on Form 20-F for the year ended December 31, 2024, for comprehensive risk factors and historical data.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers, noting that actual results could differ materially from anticipated outcomes due to various risks. It explicitly directs investors to the risk factors outlined in the Annual Report on Form 20-F filed on May 15, 2025. The specific content of the press release incorporated by reference is not included in the provided text.
Investor Verification Checklist
- Review the full text of the press release dated April 23, 2026 (Exhibit 99.1), which is not included in this summary.
- Consult the Annual Report on Form 20-F for the year ended December 31, 2024, for detailed risk factors and financial history.
- Verify the status of the registration statements on Form F-3 (No. 333-291644) and Form S-8 (Nos. 333-255124 and 333-272515) to understand the context of the incorporation by reference.